Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIC HO-YIN LEE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1609211838
CMS profile
2782560
Location
FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$23,645.10

370 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $6,367.48 29
PFIZER INC. $3,512.15 16
ADC Therapeutics America, Inc. $2,000.00 1
Genmab U.S., Inc. $1,822.83 4
Novartis Pharmaceuticals Corporation $1,681.77 37
SERVIER PHARMACEUTICALS LLC $1,582.66 6
Janssen Biotech, Inc. $535.53 24
Alexion Pharmaceuticals, Inc. $530.26 16
Merck Sharp & Dohme LLC $492.64 18
Takeda Pharmaceuticals U.S.A., Inc. $398.45 15
Eisai Inc. $291.98 12
Daiichi Sankyo Inc. $286.56 11
Exelixis Inc. $271.65 10
Gilead Sciences, Inc. $269.45 11
ABBVIE INC. $254.08 17
Incyte Corporation $245.15 9
GlaxoSmithKline, LLC. $210.88 10
Lilly USA, LLC $208.85 8
Astellas Pharma US Inc $186.70 7
Regeneron Healthcare Solutions, Inc. $176.04 6
E.R. Squibb & Sons, L.L.C. $166.33 16
BeiGene USA, Inc. $154.66 5
Kite Pharma, Inc. $128.09 4
Karyopharm Therapeutics Inc. $122.87 5
Boehringer Ingelheim Pharmaceuticals, Inc. $122.29 5
ARRAY BIOPHARMA INC $120.41 7
Genentech USA, Inc. $114.68 4
PUMA BIOTECHNOLOGY, INC. $110.85 4
Aveo Pharmaceuticals, Inc. $108.63 4
Coherus Biosciences Inc. $103.38 5
SpringWorks Therapeutics, Inc. $97.34 3
Rigel Pharmaceuticals, Inc. $92.08 4
Celgene Corporation $91.24 5
GENZYME CORPORATION $82.90 4
SANOFI-AVENTIS U.S. LLC $69.99 1
Stemline Therapeutics Inc. $69.06 2
Bayer Healthcare Pharmaceuticals Inc. $65.90 4
SOBI, INC $58.00 3
EMD Serono, Inc. $57.58 2
Ipsen Biopharmaceuticals, Inc $57.16 3
JAZZ PHARMACEUTICALS INC. $52.44 2
Boston Scientific Corporation $49.10 1
RECORDATI_RARE_DISEASES_INC. $45.10 2
TAIHO ONCOLOGY, INC. $40.16 2
TerSera Therapeutics LLC $34.36 1
PharmaEssentia USA Corporation $31.40 1
Geron Corporation $22.72 1
Fennec Pharmaceuticals, Inc. $22.66 1
Mirati Therapeutics, Inc. $16.44 1
Emmaus Medical, Inc. $12.17 1

Page 3 of 8; records 101–150 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIC HO-YIN LEE

NPI 1609211838 · CMS profile ID 2782560

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609211838?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIC HO-YIN LEE, NPI 1609211838, CMS profile ID 2782560. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609211838?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ERIC HO-YIN LEE, NPI 1609211838, CMS profile ID 2782560. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609211838?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ERIC HO-YIN LEE, NPI 1609211838, CMS profile ID 2782560, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1609211838?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

370 matching records · $23,645.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 370 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 370.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $15.9009/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114097859 CMS
AstraZeneca Pharmaceuticals LP $2,055.0009/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105849330 CMS
Aveo Pharmaceuticals, Inc. $38.2209/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143477237 CMS
Genmab U.S., Inc. $1,690.0009/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826404 CMS
Genmab U.S., Inc. $28.8109/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826406 CMS
Genmab U.S., Inc. $75.3309/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826408 CMS
PUMA BIOTECHNOLOGY, INC. $27.5609/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113845467 CMS
Kite Pharma, Inc. $29.0308/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128614573 CMS
PFIZER INC. $18.0508/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131872903 CMS
PharmaEssentia USA Corporation $31.4008/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137302396 CMS
Daiichi Sankyo Inc. $25.9008/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089447950 CMS
Merck Sharp & Dohme LLC $24.9308/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141683379 CMS
Lilly USA, LLC $29.4208/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136171308 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.4108/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118077094 CMS
Janssen Biotech, Inc. $9.0708/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078296111 CMS
Astellas Pharma US Inc $29.8508/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139405629 CMS
EMD Serono, Inc. $30.4808/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120261828 CMS
Merck Sharp & Dohme LLC $8.7908/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141683529 CMS
BeiGene USA, Inc. $33.8608/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120861461 CMS
Novartis Pharmaceuticals Corporation $99.7008/23/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086964762 CMS
Incyte Corporation $29.2008/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141286249 CMS
JAZZ PHARMACEUTICALS INC. $24.1208/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222870 CMS
Janssen Biotech, Inc. $19.2908/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078295463 CMS
AstraZeneca Pharmaceuticals LP $23.0708/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105786596 CMS
Eisai Inc. $33.7408/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110744423 CMS
Regeneron Healthcare Solutions, Inc. $35.0508/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114097855 CMS
Rigel Pharmaceuticals, Inc. $25.5008/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145203943 CMS
Gilead Sciences, Inc. $23.0708/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133805971 CMS
Eisai Inc. $30.9808/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110744425 CMS
Exelixis Inc. $23.2408/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138557625 CMS
GENZYME CORPORATION $23.4008/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139909543 CMS
Stemline Therapeutics Inc. $35.4008/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142959658 CMS
Alexion Pharmaceuticals, Inc. $34.0608/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094018685 CMS
AstraZeneca Pharmaceuticals LP $2,055.0008/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104772066 CMS
Novartis Pharmaceuticals Corporation $22.0008/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087152120 CMS
ABBVIE INC. $14.3808/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104151692 CMS
AstraZeneca Pharmaceuticals LP $34.7808/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105597619 CMS
Novartis Pharmaceuticals Corporation $24.4608/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087152114 CMS
E.R. Squibb & Sons, L.L.C. $8.3708/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101354998 CMS
Daiichi Sankyo Inc. $28.3608/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089447932 CMS
Ipsen Biopharmaceuticals, Inc $14.0108/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091963209 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.0908/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086256936 CMS
PFIZER INC. $17.7308/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131851415 CMS
ARRAY BIOPHARMA INC $15.0007/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131814906 CMS
Lilly USA, LLC $29.4207/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134972921 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.0307/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144961570 CMS
Coherus Biosciences Inc. $21.9007/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147276360 CMS
Exelixis Inc. $21.2307/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138557627 CMS
RECORDATI_RARE_DISEASES_INC. $23.5407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139164196 CMS
E.R. Squibb & Sons, L.L.C. $11.4707/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101354990 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,624.31 77
PY2020 $10,154.86 260
PY2021 $10,637.54 342
PY2022 $9,330.69 404
PY2023 $21,513.62 356
PY2024 $23,645.10 370
PY2025 $27,248.00 368

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $283,697.47 73
PY2024 Principal investigator $126,011.15 68
PY2023 Principal investigator $174,823.42 23
PY2022 Principal investigator $69,787.74 7
PY2021 Principal investigator $25,807.50 9
PY2020 Principal investigator $51,161.40 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $144.00 12/31/2025 Non-covered Recipient Entity
LOS ANGELES CANCER NETWORK
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202534429
Principal investigator 1 Genentech, Inc. $19,500.00 10/15/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC ONEONCOLOGY PARENT HLDG LLC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211635306
Principal investigator 1 PFIZER INC. $10,940.00 09/19/2025 Non-covered Recipient Entity
Los Angeles Cancer Network LACN
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717135
Principal investigator 1 PFIZER INC. $32,997.51 09/19/2025 Non-covered Recipient Entity
Los Angeles Cancer Network LACN
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717137
Principal investigator 1 ABBVIE INC. $592.00 09/16/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202510996
Principal investigator 1 GlaxoSmithKline, LLC. $4,658.36 09/16/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168334
Principal investigator 1 ABBVIE INC. $5,217.00 09/11/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202510624
Principal investigator 1 ABBVIE INC. $315.90 09/04/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202508680
Principal investigator 1 GlaxoSmithKline, LLC. $4,658.36 08/22/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168316
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 07/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166070
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 07/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192169761
Principal investigator 1 GlaxoSmithKline, LLC. $2,329.18 07/14/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166082
Principal investigator 1 GlaxoSmithKline, LLC. $2,329.18 06/18/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166062
Principal investigator 1 GlaxoSmithKline, LLC. $2,329.18 05/12/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166085
Principal investigator 1 GlaxoSmithKline, LLC. $2,329.18 05/12/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192170170
Principal investigator 1 GlaxoSmithKline, LLC. $1,690.00 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192165140
Principal investigator 1 GlaxoSmithKline, LLC. $1,430.00 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166535
Principal investigator 1 GlaxoSmithKline, LLC. $3,790.80 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166553
Principal investigator 1 GlaxoSmithKline, LLC. $1,326.00 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168289
Principal investigator 1 GlaxoSmithKline, LLC. $1,374.10 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168293
Principal investigator 1 GlaxoSmithKline, LLC. $1,710.80 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168300
Principal investigator 1 GlaxoSmithKline, LLC. $1,690.00 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168307
Principal investigator 1 GlaxoSmithKline, LLC. $2,216.50 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168311
Principal investigator 1 GlaxoSmithKline, LLC. $551.20 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168351
Principal investigator 1 GlaxoSmithKline, LLC. $334.10 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192169773
Principal investigator 1 GlaxoSmithKline, LLC. $334.10 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192169777
Principal investigator 1 GlaxoSmithKline, LLC. $1,326.00 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192169781
Principal investigator 1 GlaxoSmithKline, LLC. $325.00 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192169789
Principal investigator 1 GlaxoSmithKline, LLC. $1,690.00 05/09/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192170155
Principal investigator 1 ABBVIE INC. $19,983.60 05/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482029
Principal investigator 1 ABBVIE INC. $1,579.50 05/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482031
Principal investigator 1 ABBVIE INC. $15,083.90 05/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482033
Principal investigator 1 ABBVIE INC. $11,841.70 05/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482109
Principal investigator 1 ABBVIE INC. $12,175.10 05/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482111
Principal investigator 1 ABBVIE INC. $12,008.60 05/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482113
Principal investigator 1 ABBVIE INC. $3,694.30 05/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482115
Principal investigator 1 ABBVIE INC. $8,074.30 05/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202482117
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192165124
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192165128
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192165131
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192165136
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166058
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166066
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166075
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166078
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166546
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166557
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168297
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168321
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168325
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168330
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168339
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168342
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192169765
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192169785
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192170159
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192170163
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192170174
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192170179
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 04/28/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192170183
Principal investigator 1 GlaxoSmithKline, LLC. $2,329.18 04/08/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192170165
Principal investigator 1 GlaxoSmithKline, LLC. $325.00 03/21/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166542
Principal investigator 1 GlaxoSmithKline, LLC. $439.40 03/21/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166549
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 03/21/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166561
Principal investigator 1 GlaxoSmithKline, LLC. $1,430.00 03/21/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168304
Principal investigator 1 GlaxoSmithKline, LLC. $1,374.10 03/21/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192168346
Principal investigator 1 GlaxoSmithKline, LLC. $551.20 03/21/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192169769
Principal investigator 1 ABBVIE INC. $20,151.30 03/06/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202456656
Principal investigator 1 AstraZeneca UK Limited $38,044.64 02/24/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
a phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell lung cancer whose disease has progressed on prior osimertinib treatment tropion lung15 No dispute reported 06/30/2026 1185550990
Principal investigator 1 ABBVIE INC. $10,687.30 02/05/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RES GROUP INC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202445804
Principal investigator 1 GlaxoSmithKline, LLC. $4,658.36 02/05/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192165144
Principal investigator 1 GlaxoSmithKline, LLC. $4,658.36 01/08/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192165149
Principal investigator 1 GlaxoSmithKline, LLC. $2,329.18 01/08/2025 Non-covered Recipient Entity
COMPASSIONATE CARE RESEARCH GROUP INC
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192166565